Looking to hire a lab manager/technician for the new lab at Dana Farber. Please apply to join our group focused on engineering new cell therapies, especially for pediatric cancer. Job description is flexible - experience with mice and T cells preferred. careers.dana-farber.org/job/senior-res…

CRISPR-based medicine. So much more to come.

Congrats Holly Lee , nizar jacques bahlis on this important and timely work on TCE resistance.

!!!!!!!!

#ASH23 BMS-986393, GPRC5D–CAR-T for RRMM. N=70, ORR; 86%, 75% with prior BCMA-directed Rx. Skin/nail AE: 40%, dysgeusia: 3% Susan Bal Omar Nadeem Larry Anderson,MD,PhD,FACP #mmsm #bmtsm ash.confex.com/ash/2023/webpr…

Gene editing for hemophilia: gorgeous data from Intellia Therapeutics Regeneron #ASH23. Next-generation #CRISPR-based approach leveraging advances in liver editing! Robust advantages over conventional AAV. On a path to clinical trial initiation. 1. Woo. 2. Hoo! ash.confex.com/ash/2023/webpr…

Amazing presentation Susan Bal. Kudos to PIs, clinical teams, and Bristol Myers Squibb team. So excited to see the high response rate, ongoing responses, and low infectious rate with our GPRC5D CAR; many with prior BCMA tx. #mmsm #ash23 Omar Nadeem Jesus Berdeja, MD Tom Martin Dana-Farber News

Very high activity with little disgeusia and skin toxicity. CAR-T may be the best way to hit GPRC5D. Terrific presentation by ⁦Susan Bal⁩ #ASH23 ⁦Jesus Berdeja, MD⁩ ⁦Larry Anderson,MD,PhD,FACP⁩ ⁦Omar Nadeem⁩

Since it has come up in discussions a lot at #ash23, my thoughts on FDA investigation of secondary T cell malignancies post-CAR T can be found The Lancet Oncology: thelancet.com/journals/lanon… and in more detail: news.harvard.edu/gazette/story/… tldr:benefits>>>risks Marco Ruella @DrMiguelPerales

Amazing being part of IOTN Moonshot thank you to all who made this incredible network possible.

Thanks Robin Shattock for bringing this to our attention. There is no evidence that mRNA vaccines cause cancer and these claims should not be a hurdle to progress with RNA technology being developed to benefit our patients.

Congrats to CAR T pioneers for work done Memorial Sloan Kettering Cancer Center (where I was lucky enough to get my start): Renier Brentjens, Michel Sadelain, as well as Carl June (pennmed) and Zelig Eshhar (Weizmann Institute) on winning the 2024 Warren Alpert Prize for CAR T cell tx! Well deserved!

Join me as I present with Karl Petri, Prof. Dr. Hermann Einsele, and Chiara Bonini. Starting soon. #EHA24

Participated recently in the The White House Cell & Gene Therapy Forum. Patient advocates, rare disease families were inspiring. Massive science advances (CAR T, sickle cell GT). Need to ensure ACCESS. Scientific AND policy solutions must be prioritized. #WhiteHouseCGT h/t Kamal Menghrajani, MD, MS.

Congratulations to Eric Smith, MD, PhD, Dana-Farber on receiving the Outstanding New Investigator Award from ASGCT. Smith will present on advancing CAR T cell therapy for cancer immunotherapy. #ASGCT2025

Congrats ⁦Elizabeth Carstens MD⁩ on your outstanding presentation on engineering novel CARs to enhance the therapeutic window of CAR T cells for GI malignancies. #asgct2025 #asgct25 ⁦Dana-Farber News⁩

Congrats ⁦Elliott Brea MD, PhD⁩ on awesome work and an awesome presentation showing how CAR T cell therapy can overcome ADC resistance in solid tumors and engineering rational biparatopic CARs. #asgct2025 #asgct25 ⁦Dana-Farber News⁩

Amazing work Ko-Wei Liu and the collaborative team to engineer CAR T cells where persistence is controlled by leveraging ⁦Cue Biopharma⁩ recombinant ImmunoSTATs to specifically deliver TCR+cytokine signals to our engineered cells. #asgct25 #asgct2025 ⁦Dana-Farber News⁩

Honored to be recognized w/ past + current Investigators Rebecca Ahrens-Nicklas Xavier Anguela, PhD & DevermanLab. Award is to our entire Dana-Farber gene and cell therapy team & the huge teams of colleagues past/present who work to bring these therapies from ideas in the lab to patients.